Breaking Finance News

Exelixis (NASDAQ:EXEL) stock price target upped to $33.00, released a report earlier today by Needham

In a report released on 10/17/2017 Needham increased the target price of Exelixis (NASDAQ:EXEL) from $30.00 to $33.00 stating a potential upside of 0.14%.

On 10/16/2017, SunTrust released a statement for Exelixis (NASDAQ:EXEL) upped the target price from $32.00 to $35.00. At the time, this indicated a possible upside of 0.41%.

Yesterday Exelixis (NASDAQ:EXEL) traded -1.03% lower at $29.02. The company’s 50-day moving average is $26.24 and its two hundred day average is $23.95. With the last stock price close up 19.93% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same period. Trade Volume was up over the average, with 4,851,358 shares of EXEL changing hands over the typical 3,371,070

See Chart Below

Exelixis (NASDAQ:EXEL)

With a total market value of $0, Exelixis has PE ratio of 145.05 with a one year low of $10.04 and a one year high of $30.20 .

A total of 3 brokers have issued a research note on EXEL. Three equity analysts rating the company a strong buy, one brokerage rating the company a buy, one analyst rating the company a hold, zero analysts rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $7.00.

General Company Details For Exelixis (NASDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.